FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:543-544 August 12, 1999 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

To the Editor: Progressive supranuclear palsy is an atypical Parkinsonian syndrome characterized by motor symptoms (voluntary-eye-movement abnormalities, akinesia, rigidity, postural instability, dysarthria, and dysphagia), personality changes, and cognitive impairment. It is refractory to pharmacologic treatment. Since reduced neurotransmission of -aminobutyric acid (GABA) in the striatum and globus pallidus could contribute to the symptoms of progres-sive supranuclear palsy, drugs that act specifically on the GABAergic systems in the basal ganglia might be helpful in the disorder.¹

Zolpidem, a short-acting hypnotic drug, can improve motor symptoms in patients with Parkinson's disease.² This GABAergic drug is a selective agonist of the benzodiazepine subtype . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Evidente, V. G. H. (2002). Zolpidem improves dystonia in ""Lubag"" or X-linked dystonia-parkinsonism syndrome. Neurology 58: 662-663 [Full Text]  
• Cavalheiro, E. A., Olney, J. W. (2001). Glutamate antagonists: Deadly liaisons with cancer. Proc. Natl. Acad. Sci. USA 98: 5947-5948 [Full Text]